Skip to main content
NCBI home page
Cell Regulation logoLink to Cell Regulation
. 1990 Nov;1(12):895–905. doi: 10.1091/mbc.1.12.895

Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.

J Bizik 1, A Lizonová 1, R W Stephens 1, M Grófová 1, A Vaheri 1
PMCID: PMC362860  PMID: 1712633

Abstract

Several human melanoma cell lines produced tissue-type plasminogen activator (t-PA), as detected by zymography and immunocapture assay of culture media and cell lysates. Urokinase (u-PA) was found at only less than or equal to 1% the level of t-PA. Acid eluates of the cell surface indicated that the melanoma cells had t-PA bound on their surface, but no u-PA, and also had a very low capacity to bind exogenous u-PA. After incubation of the melanoma cells with 10% plasminogen-depleted fetal calf serum and human plasminogen, bound plasmin activity could be eluted from the cell surface with tranexamic acid, an analogue of lysine. This indicated that plasminogen was activated on the cell surface. The cell-surface plasmin formation was inhibited by an anti-catalytic monoclonal antibody to human t-PA, and not by an anti-catalytic antibody to u-PA. The melanoma cells also synthesized and secreted alpha 2-macroglobulin (alpha 2M), as shown by alpha 2M-specific mRNA in Northern blotting and detection of alpha 2M protein in conditioned cell culture media. The media were found to inhibit u-PA but not t-PA. This inhibition was related to their alpha 2M content, and immunoabsorption of alpha 2M removed the inhibitory activity. These studies suggest that t-PA can bind to the surface of melanoma cells and generate surface-bound plasmin. Because t-PA and cell-bound plasmin are unaffected by alpha 2M, t-PA may, in the case of melanoma cells, serve an analogous function to u-PA in supporting tumor cell invasion.

Full text

PDF
895

Images in this article

897Image
on p.897
901Image
on p.901
902Image
on p.902

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen R. A. An enhancing effect of poly-lysine on the activation of plasminogen. Thromb Haemost. 1982 Feb 26;47(1):41–45. [PubMed] [Google Scholar]
  2. Auffray C., Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 1980 Jun;107(2):303–314. doi: 10.1111/j.1432-1033.1980.tb06030.x. [DOI] [PubMed] [Google Scholar]
  3. Barnathan E. S., Kuo A., Van der Keyl H., McCrae K. R., Larsen G. R., Cines D. B. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. J Biol Chem. 1988 Jun 5;263(16):7792–7799. [PubMed] [Google Scholar]
  4. Bonner W. M., Laskey R. A. A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem. 1974 Jul 1;46(1):83–88. doi: 10.1111/j.1432-1033.1974.tb03599.x. [DOI] [PubMed] [Google Scholar]
  5. Bízik J., Lizonová A., Grófová M., Matoŝka J., Doré J. F., Bertrand S., Blaŝko M., Vaheri A. Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation. Cancer Res. 1989 Feb 15;49(4):983–990. [PubMed] [Google Scholar]
  6. Bízik J., Vaheri A., Saksela O., Kalkkinen N., Meri S., Grófóva M. Human tumor cells synthesize and secrete alpha-2-macroglobulin in vitro. Int J Cancer. 1986 Jan 15;37(1):81–88. doi: 10.1002/ijc.2910370114. [DOI] [PubMed] [Google Scholar]
  7. Cassiman J. J., van Leuven F., van der Schueren B., van den Berghe H. Immunohistochemical localization of human alpha 2Macroglobulin in connective tissue. Cell Tissue Res. 1980;213(2):301–310. doi: 10.1007/BF00234789. [DOI] [PubMed] [Google Scholar]
  8. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  9. Deguchi K., Shirakawa S. Plasminogen activation by tissue plasminogen activator in the presence of platelets. Thromb Res Suppl. 1988;8:65–72. doi: 10.1016/0049-3848(88)90155-7. [DOI] [PubMed] [Google Scholar]
  10. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  11. Granelli-Piperno A., Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med. 1978 Jul 1;148(1):223–234. doi: 10.1084/jem.148.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Green G. D., Shaw E. Thiobenzyl benzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. Anal Biochem. 1979 Mar;93(2):223–226. doi: 10.1016/s0003-2697(79)80141-4. [DOI] [PubMed] [Google Scholar]
  13. Grøndahl-Hansen J., Ralfkiaer E., Nielsen L. S., Kristensen P., Frentz G., Danø K. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol. 1987 Jan;88(1):28–32. doi: 10.1111/1523-1747.ep12464827. [DOI] [PubMed] [Google Scholar]
  14. Hajjar K. A., Hamel N. M., Harpel P. C., Nachman R. L. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest. 1987 Dec;80(6):1712–1719. doi: 10.1172/JCI113262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hoal-Van Helden E. G., Wilson E. L., Dowdle E. B. Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators. Br J Cancer. 1986 Aug;54(2):287–295. doi: 10.1038/bjc.1986.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hoal E. G., Wilson E. L., Dowdle E. B. The regulation of tissue plasminogen activator activity by human fibroblasts. Cell. 1983 Aug;34(1):273–279. doi: 10.1016/0092-8674(83)90158-7. [DOI] [PubMed] [Google Scholar]
  17. Holmberg L., Lecander I., Astedt B. Binding of urokinase to plasma proteinase inhibitors. Scand J Clin Lab Invest. 1980;40(8):743–747. doi: 10.3109/00365518009095590. [DOI] [PubMed] [Google Scholar]
  18. Hovi T., Mosher D., Vaheri A. Cultured human monocytes synthesize and secrete alpha2-macroglobulin. J Exp Med. 1977 Jun 1;145(6):1580–1589. doi: 10.1084/jem.145.6.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Huarte J., Belin D., Vassalli J. D. Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell. 1985 Dec;43(2 Pt 1):551–558. doi: 10.1016/0092-8674(85)90184-9. [DOI] [PubMed] [Google Scholar]
  20. Jacubovich R., Cabrillat H., Gerlier D., Bailly M., Doré J. F. Tumourigenic phenotypes of human melanoma cell lines in nude mice determined by an active antitumour mechanism. Br J Cancer. 1985 Mar;51(3):335–345. doi: 10.1038/bjc.1985.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jänicke F., Schmitt M., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet. 1989 Oct 28;2(8670):1049–1049. doi: 10.1016/s0140-6736(89)91070-2. [DOI] [PubMed] [Google Scholar]
  22. Korninger C., Collen D. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemost. 1981 Oct;46(3):662–665. [PubMed] [Google Scholar]
  23. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  24. Leung K. C., Byatt J. A., Stephens R. W. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin). Thromb Res. 1987 Jun 15;46(6):755–766. doi: 10.1016/0049-3848(87)90068-5. [DOI] [PubMed] [Google Scholar]
  25. Matoŝka J., Wahlström T., Vaheri A., Bízik J., Grófová M. Tumor-associated alpha-2-macroglobulin in human melanomas. Int J Cancer. 1988 Mar 15;41(3):359–363. doi: 10.1002/ijc.2910410307. [DOI] [PubMed] [Google Scholar]
  26. Mignatti P., Robbins E., Rifkin D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986 Nov 21;47(4):487–498. doi: 10.1016/0092-8674(86)90613-6. [DOI] [PubMed] [Google Scholar]
  27. Morgan A. C., Jr alpha 2-macroglobulin production by cultured human melanoma cells. J Natl Cancer Inst. 1984 Mar;72(3):557–562. [PubMed] [Google Scholar]
  28. Mosher D. F., Saksela O., Vaheri A. Synthesis and secretion of alpha-2-macroglobulin by cultured adherent lung cells. Comparison with cell strains derived from other tissues. J Clin Invest. 1977 Nov;60(5):1036–1045. doi: 10.1172/JCI108854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Neuman T., Stephens R. W., Salonen E. M., Timmusk T., Vaheri A. Induction of morphological differentiation of human neuroblastoma cells is accompanied by induction of tissue-type plasminogen activator. J Neurosci Res. 1989 Jul;23(3):274–281. doi: 10.1002/jnr.490230305. [DOI] [PubMed] [Google Scholar]
  30. Nielsen L. S., Kellerman G. M., Behrendt N., Picone R., Danø K., Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem. 1988 Feb 15;263(5):2358–2363. [PubMed] [Google Scholar]
  31. Ogston D., Bennett B., Herbert R. J., Douglas A. S. The inhibition of urokinase by alpha 2 -macroglobulin. Clin Sci. 1973 Jan;44(1):73–79. doi: 10.1042/cs0440073. [DOI] [PubMed] [Google Scholar]
  32. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell. 1988 Feb 12;52(3):321–328. doi: 10.1016/s0092-8674(88)80025-4. [DOI] [PubMed] [Google Scholar]
  33. Pöllänen J., Vaheri A., Tapiovaara H., Riley E., Bertram K., Woodrow G., Stephens R. W. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2230–2234. doi: 10.1073/pnas.87.6.2230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
  35. Siracký J., Blasko M., Borovanský J., Kovarík J., Svec J., Vrba M. Human melanoma cell lines: morphology, growth, and alpha-mannosidase characteristics. Neoplasma. 1982;29(6):661–668. [PubMed] [Google Scholar]
  36. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  37. Stephens R. W., Pöllänen J., Tapiovaara H., Leung K. C., Sim P. S., Salonen E. M., Rønne E., Behrendt N., Danø K., Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989 May;108(5):1987–1995. doi: 10.1083/jcb.108.5.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Stephens R., Leung K. C., Pöllänen J., Salonen E. M., Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods. 1987 Dec 24;105(2):245–251. doi: 10.1016/0022-1759(87)90272-9. [DOI] [PubMed] [Google Scholar]
  39. Stoppelli M. P., Tacchetti C., Cubellis M. V., Corti A., Hearing V. J., Cassani G., Appella E., Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell. 1986 Jun 6;45(5):675–684. doi: 10.1016/0092-8674(86)90782-8. [DOI] [PubMed] [Google Scholar]
  40. Straight D. L., Hassett M. A., McKee P. A. Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin. Biochemistry. 1985 Jul 16;24(15):3902–3907. doi: 10.1021/bi00336a014. [DOI] [PubMed] [Google Scholar]
  41. Suenson E., Petersen L. C. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta. 1986 Apr 22;870(3):510–519. doi: 10.1016/0167-4838(86)90260-8. [DOI] [PubMed] [Google Scholar]
  42. Svec J., Veselovská Z., Keszeghová V., Matoska J., Marchetti A., Squartini F. Biological and immunological properties of the HMB-2 human melanoma cell line. Neoplasma. 1988;35(6):665–681. [PubMed] [Google Scholar]
  43. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wagner O. F., Vetterlein M., Binder B. R. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J Biol Chem. 1986 Nov 5;261(31):14474–14481. [PubMed] [Google Scholar]
  45. White R., Janoff A., Godfrey H. P. Secretion of Alpha-2-macroglobulin by human alveolar macrophages. Lung. 1980;158(1):9–14. doi: 10.1007/BF02713697. [DOI] [PubMed] [Google Scholar]

Articles from Cell Regulation are provided here courtesy of American Society for Cell Biology

RESOURCES